Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexia Iasonos

Showing results (1-10 of 269) with videos related to

Pageof 27
Sort By:
The Oncologist|September 2, 2020
Finding Optimism in Clinical Trials: A Numbers PerspectiveAlexia Iasonos
British Journal of Cancer|June 11, 2021
Randomised Phase 1 clinical trials in oncologyAlexia Iasonos, John O'Quigley
Statistics in Medicine|August 16, 2012
Interplay of priors and skeletons in two-stage continual reassessment methodAlexia Iasonos, John O'Quigley
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2014
Adaptive dose-finding studies: a review of model-guided phase I clinical trialsAlexia Iasonos, John O'Quigley
Statistics in Medicine|February 26, 2011
Continual reassessment and related designs in dose-finding studiesAlexia Iasonos, John O'Quigley
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Design considerations for dose-expansion cohorts in phase I trialsAlexia Iasonos, John O'Quigley
Statistics in Medicine|February 23, 2011
Estimating the dose-toxicity curve in completed phase I studiesAlexia Iasonos, Irina Ostrovnaya
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2022
Statistics in OncologySean Devlin, Alexia Iasonos
Nature Reviews. Clinical Oncology|October 7, 2015
Clinical trials: Early phase clinical trials-are dose expansion cohorts needed?Alexia Iasonos, John O'Quigley
Journal of the Royal Statistical Society. Series C, Applied Statistics|November 1, 2017
Phase I Designs that Allow for Uncertainty in the Attribution of Adverse EventsAlexia Iasonos, John O'Quigley
Pageof 27

Showing results (1-10 of 269) with videos related to

Sort By:
Pageof 27
The Oncologist|September 2, 2020
Finding Optimism in Clinical Trials: A Numbers PerspectiveAlexia Iasonos
British Journal of Cancer|June 11, 2021
Randomised Phase 1 clinical trials in oncologyAlexia Iasonos, John O'Quigley
Statistics in Medicine|August 16, 2012
Interplay of priors and skeletons in two-stage continual reassessment methodAlexia Iasonos, John O'Quigley
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2014
Adaptive dose-finding studies: a review of model-guided phase I clinical trialsAlexia Iasonos, John O'Quigley
Statistics in Medicine|February 26, 2011
Continual reassessment and related designs in dose-finding studiesAlexia Iasonos, John O'Quigley
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 9, 2013
Design considerations for dose-expansion cohorts in phase I trialsAlexia Iasonos, John O'Quigley
Statistics in Medicine|February 23, 2011
Estimating the dose-toxicity curve in completed phase I studiesAlexia Iasonos, Irina Ostrovnaya
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2022
Statistics in OncologySean Devlin, Alexia Iasonos
Nature Reviews. Clinical Oncology|October 7, 2015
Clinical trials: Early phase clinical trials-are dose expansion cohorts needed?Alexia Iasonos, John O'Quigley
Journal of the Royal Statistical Society. Series C, Applied Statistics|November 1, 2017
Phase I Designs that Allow for Uncertainty in the Attribution of Adverse EventsAlexia Iasonos, John O'Quigley
Pageof 27